Skip to NavigationSkip to content

News

Canadian pharmaceutical firm Valeant has announced the list price for its psoriasis treat Siliq (brodalumab) will stand at $3,500 a month, in an...
Researchers from the Universities of Exeter and Alberta have identified a protein in the brain which they believe could be key in the onset of...
Actelion has revealed that, following the wrap of its $30 billion deal in January, Janssen Holding has acquired 92.51% of its shares, according to...
Sanofi and Regeneron are celebrating the news that their treatment Kevzara (sarilumab) has received a positive opinion from the EMA’s Committee for...
Bristol-Myers Squibb’s UK General Manager Ben Hickey has slammed NICE over its assessment criteria and process in recommending access to life-...
In a deal that sounds more like something to come out of a science-fiction novel, Applied DNA Sciences has agreed a five-year deal with an unnamed...
The FDA has announced that it will require medication including codeine and tramadol, two high-strength painkillers, to have its strongest warning on...
From Novartis and Allergan's new partnership to tackle NASH to some shocking trial results from AbbVie and Circassia, check out the top ten most...
GSK has been anticipating competition to its Advair for two years and Teva has announced that it will be the first to introduce a competitor, after...
Deal-making in the global pharmaceuticals sector is booming, with no signs of slowing down.